Trials / Recruiting
RecruitingNCT05019625
Biomarker Development for Muscular Dystrophies
- Status
- Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 465 (estimated)
- Sponsor
- Massachusetts General Hospital · Academic / Other
- Sex
- All
- Age
- 5 Years
- Healthy volunteers
- Accepted
Summary
Current methods of measuring the response to new treatments for muscular dystrophies involve the examination of small pieces of muscle tissue called biopsies. The investigators are interested in finding less invasive methods that reduce the need for muscle biopsies. The purpose of this research is to learn about the possibility of detecting and measuring the activity and severity of muscular dystrophies by examining a urine sample and a blood sample, and some muscles in the arms and legs using tests called ultrasound and electrical impedance myography; both tests are painless and non-invasive. The information that is gathered from this study may help to evaluate, prevent, diagnose, treat, and improve the understanding of human muscle diseases.
Conditions
- Myotonic Dystrophy
- Duchenne Muscular Dystrophy
- Becker Muscular Dystrophy
- Facioscapulohumeral Muscular Dystrophy
Timeline
- Start date
- 2015-02-20
- Primary completion
- 2027-06-01
- Completion
- 2028-06-01
- First posted
- 2021-08-25
- Last updated
- 2025-11-24
Locations
5 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT05019625. Inclusion in this directory is not an endorsement.